Caption
: Recruiting trial
= 
; Ongoing trial
= 
-
- LOGiC : A phase III study of ErbB2 positive advanced or metastatic gastric or esophageal or gastroesophageal junction adenocarcinoma treated with capecitabine plus oxaliplatin with or without lapatinib
- North Estonia Regional Hospital
- Internal Medicine Clinic, Oncology department
- More details
-
- IMAGE. Phase Ib/II, multicenter, open-label, randomized, clinical study with dose optimization of two different schedules of elisidepsin trifluoroacetate (Irvalec®) as a single agent in patients with unresectable, locally advanced or metastatic esophageal, esophagogastric junction or gastric cancer after failure of one but not more than two prior lines of systemic therapy - FR
- CHU de Brest - Hôpital Morvan
- Institut de Cancérologie et d'Hématologie
- More details
-
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- ToGA Study : A Randomized, Open-label Study of the Effect of First-line Herceptin in Combination With a Fluoropyrimidine and Cisplatin Versus Chemotherapy Alone on Overall Survival in Patients With HER2-positive Advanced Gastric Cancer (Phase III) -FR -
- Not yet identified - FR
- More details
-
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- A randomized, double-blind, multi-center phase III study comparing everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in patients with advanced gastric cancer after progression on prior systemic chemotherapy
- Not yet identified - FR
- More details
-
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- A randomized, open-label, multi-center phase II study to compare AUY922 with docetaxel or irinotecan in adult patients with advanced gastric cancer, who have progressed after one line of chemotherapy - FR
- Not yet identified - FR
- More details
-
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- RAINBOW - A randomized, multicenter, double-blind, placebo-controlled phase 3 study of weekly paclitaxel with or without ramucirumab (IMC-1121B) drug product in patients with metastatic gastric adenocarcinoma, refractory to or progressive after first-line therapy with platinum and fluoropyrimidine - FR
- Not yet identified - FR
- More details
-
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- IPEC_GC : A phase II trial evaluating the efficacy of preoperative chemotherapy with paclitaxel dose-dense cisplatin and epirubicin (increased PET protocol) in gastric or lower esophagus adenocarcinoma - FR
- Not yet identified - FR
- More details
-
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- Prospective, multicentre, open-label, randomised, uncontrolled, phase 1/2 study to evaluate efficacy and safety of masitinib in combination as second line chemotherapy in patients with gastric or gastro-oesophageal junction metastatic adenocarcinoma - FR
- Not yet identified - FR
- More details
-
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- A randomized, open-label, multi-center phase II study to compare AUY922 with docetaxel or irinotecan in adult patients with advanced gastric cancer, who have progressed after one line of chemotherapy - FR
- Not yet identified - FR
- More details
-
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- Phase Ib/II, Multicenter, Open-Label, Randomized, Clinical Study with Dose Optimization of Two Different Schedules of Elisidepsin Trifluoroacetate (Irvalec®) as a Single Agent in Patients with Unresectable, Locally Advanced or Metastatic Esophageal, Esophagogastric Junction or Gastric Cancer After Failure of One but not More than Two Prior Lines of Systemic Therapy - FR
- Not yet identified - FR
- More details
-
- GERMANY
- Niedersachsen
- BRAUNSCHWEIG
- Phase III Study: Cetuximab in combination with capecitabine and cisplatin versus capecitabine and cisplatin alone as first-line treatment for subjects with advanced gastric adenocarcinoma including gastroesophageal junction - DE (Restarted)
- Städtisches Klinikum Braunschweig gGmbH
- Medizinische Klinik III - Hämatologie und Onkologie
- More details
-
- GERMANY
- Niedersachsen
- BRAUNSCHWEIG
- GastroLap - Lapatinib versus Lapatinib with Capecitabine as second-line treatment in Her2-overexpressing metastatic Gastro-Esophageal Cancer: A open-label multicentre randomized phase II trial
- Städtisches Klinikum Braunschweig gGmbH
- Medizinische Klinik III - Hämatologie und Onkologie
- More details
-
- GERMANY
- Nordrhein-Westfalen
- KÖLN
- Safety and efficacy study with catumaxomab in patients after curative resection of a gastric adenocarcinoma (Phase II)
- Krankenhaus Merheim, Kliniken der Stadt Köln gGmbH
- Zentrum für Chirurgie: Viszeral-, Gefäß- und Transplantationschirurgie
- More details
-
- GERMANY
- Rheinland-Pfalz
- MAINZ
- GC-DOR-2004: Phase I/II study to evaluate the safety and efficacy of a neoadjuvant radiochemotherapy with Docetaxel and Oxaliplatin in patients with adenocarcinoma of the gastric-oesophageal junction
- Universitätsmedizin Mainz
- I. Medizinische Klinik und Poliklinik
- More details
-
- GERMANY
- Sachsen-Anhalt
- HALLE (SAALE)
- Phase II trial of Docetaxel, Oxaliplatin and Capecitabine in advanced or metastatic gastric cancer
- Universitätsklinikum Halle (Saale)
- Universitätsklinik und Poliklinik für Innere Medizin IV
- More details
-
- NETHERLANDS
- Zuid-Holland
- ROTTERDAM
- A randomized phase II trial comparing epirubicin, cisplatin, and capecitabine versus the combination of epirubicin, cisplatin, and capecitabine with pravastatin in patients with irresectable or metastatic gastric carcinoma
- Erasmus MC - Erasmus Medisch Centrum
- Kankercentrum Daniel den Hoed
- More details
-
- SPAIN
- Cantabria
- SANTANDER
- A Phase 2 Open-Label Study Evaluating the Efficacy and Safety of Telatinib in Combination With Chemotherapy as First-Line Therapy in Subjects With Advanced Gastric Cancer (completed)
- HUMV - Hospital Universitario Marqués de Valdecilla
- Servicio de Oncología Médica (HUMV)
- More details
-
- SPAIN
- Cantabria
- SANTANDER
- Phase II Study of Adjusted-Dose Docetaxel-Oxaliplatin-Capecitabine in Patients With Advanced Gastric Adenocarcinoma and Intermediate General Status (completed)
- HUMV - Hospital Universitario Marqués de Valdecilla
- Servicio de Oncología Médica (HUMV)
- More details
-
- SPAIN
- Cantabria
- SANTANDER
- Phase II Study to Assess the Efficacy and Safety of Trastuzumab in Combination With Xelox as First-line Treatment of Patients With Advanced or Metastatic Gastric Cancer or Gastro-esophageal Junction, (HER2)-Positive
- HUMV - Hospital Universitario Marqués de Valdecilla
- Servicio de Oncología Médica (HUMV)
- More details
-
- SPAIN
- Cantabria
- SANTANDER
- A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction - ES
- HUMV - Hospital Universitario Marqués de Valdecilla
- Servicio de Oncología Médica (HUMV)
- More details
-
- A Phase 2 Open-Label Study Evaluating the Efficacy and Safety of Telatinib in Combination With Chemotherapy as First-Line Therapy in Subjects With Advanced Gastric Cancer (completed)
- Hospital Universitari General Vall d'Hebron
- Servicio de Oncología Médica
- More details
-
- A Phase 2 Open-Label Study Evaluating the Efficacy and Safety of Telatinib in Combination With Chemotherapy as First-Line Therapy in Subjects With Advanced Gastric Cancer (completed)
- Hospital Clínico San Carlos
- Servicio de Oncología Médica (H.C. San Carlos)
- More details
-
- A Phase 2 Open-Label Study Evaluating the Efficacy and Safety of Telatinib in Combination With Chemotherapy as First-Line Therapy in Subjects With Advanced Gastric Cancer (completed)
- Hospital Universitario 12 de Octubre
- Servicio de Oncología Médica
- More details
-
- A Phase 2 Open-Label Study Evaluating the Efficacy and Safety of Telatinib in Combination With Chemotherapy as First-Line Therapy in Subjects With Advanced Gastric Cancer (completed)
- Hospital Universitario Ramón y Cajal
- Servicio de Oncología Médica (HRC)
- More details
-
- SPAIN
- Madrid
- NOT YET IDENTIFIED - ES
- Open-label, Randomized, Controlled, Multicenter Phase III Study Investigating Cetuximab in Combination With Capecitabine (Xeloda, X) and Cisplatin (P) Versus XP Alone as First-line Treatment for Subjects With Advanced Gastric Adenocarcinoma Including Adenocarcinoma of the Gastroesophageal Junction - ES (completed)
- Not yet identified - ES
- More details
-
- SPAIN
- Madrid
- NOT YET IDENTIFIED - ES
- A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy - ES
- Not yet identified - ES
- More details
-
- SPAIN
- Madrid
- NOT YET IDENTIFIED - ES
- RAINBOW - A randomized, multicenter, double-blind, placebo-controlled phase 3 study of weekly paclitaxel with or without ramucirumab (IMC-1121B) drug product in patients with metastatic gastric adenocarcinoma, refractory to or progressive after first-line therapy with platinum and fluoropyrimidine - ES
- Not yet identified - ES
- More details
-
- SPAIN
- Madrid
- NOT YET IDENTIFIED - ES
- DIGEST: An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared With 5-FU and Cisplatin in Patients With Metastatic Diffuse Gastric Cancer Previously Untreated With Chemotherapy - ES
- Not yet identified - ES
- More details
-
- SPAIN
- Madrid
- NOT YET IDENTIFIED - ES
- A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer (Phase III) - ES
- Not yet identified - ES
- More details
-
- SPAIN
- Madrid
- NOT YET IDENTIFIED - ES
- An Open-Label, Randomized, Multicenter Phase IIa Study Evaluating Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer - ES
- Not yet identified - ES
- More details
-
- SPAIN
- Madrid
- NOT YET IDENTIFIED - ES
- An Open-label, Single-arm, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AUY922 in Combination With Trastuzumab Standard Therapy as Second-line Treatment in Patients With HER2-positive Advanced Gastric Cancer - ES (terminated)
- Not yet identified - ES
- More details
-
- SPAIN
- Madrid
- NOT YET IDENTIFIED - ES
- A Randomized, Open-label, Two-arm Phase II Trial Comparing the Efficacy of Sequential Ipilimumab Versus Best Supportive Care Following First-line Chemotherapy in Subjects With Unresectable Locally Advanced/Metastatic Gastric or Gastro-esophageal Junction Cancer - ES
- Not yet identified - ES
- More details
-
- SPAIN
- Madrid
- NOT YET IDENTIFIED - ES
- A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Onartuzumab (MetMAb) In Combination With 5-Fluorouracil, Folinic Acid, And Oxaliplatin (mFOLFOX6) In Patients With Metastatic Her2-Negative, Met-Positive Gastroesophageal Cancer - ES
- Not yet identified - ES
- More details
-
- SPAIN
- País Vasco
- SAN SEBASTIÁN
- AGIM-1: Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer (Phase IV)
- Hospital Universitario Donostia
- Departamento de Gastroenterología (H. Donostia)
- More details
